Stem Cell Therapy Treatments: Bone Marrow Transplant

Showing posts with label Bone Marrow Transplant. Show all posts

May 13, 2020

Stem Cell Therapy- Sickle Cell Anemia Treatment With Stem Cell Therapy

Apply Grants May 13, 2020 1

Stem Cell Therapy Offers A Respite From Sickle Cell Anemia

Sickle cell anemia is a hereditary blood disorder that affects mostly African-American descents. Most probably, a stem cell therapy transplant using the patient’s own stem cells for the gene alteration or correcting method can help patients with sickle cell anemia.

A large number of people can expect effective treatment results using stem cells, as though the treatment involves risks as well.

However, recent treatment of a patient with sickle cell anemia in Edmonton, Canada with stem cell therapy raises hopes for other patients too.

What Is Sickle Cell Anemia?

According to the American Society of Hematology, this genetic disorder is more prevalent in African-American descendants, which affects as many as 70,000 to 100,000 individuals. Sickle cell anemia is known as sickle cell disease as well.
Read-

Stem Cell Therapy Treatment For Adamant Cancer Cells

The disease caused by a genetic mutation in the red blood cells changes the blood cells in an abnormal manner and turns them in crescent shapes like structures. The new formation leads the blood to clot, making them get stuck in the blood vessels. As a result, many organs and parts of the body cannot get an adequate volume of blood supply, making them get exhausted with different ailments, including organ deaths, heart attacks, and kidney ailments. stem cell therapy, stem cell transplant.

The procedure of bone marrow transplant works for sickle cell anemia. It requires bone marrow from a healthy donor to replace it with the diseased one so that the marrow can produce healthier mutation-free red blood cells with no more sickle-shaped crescents.

As said earlier, the transplant comes with a risk to life. Until now, bone marrow transplant has appeared to be very toxic for adult patients. The procedure is a setback for those, who cannot accept the toxicity of the transplant as chemotherapy kills one’s strength to stand the jerk and results in damage of the marrow prior to the transplant. However, a retrospective study back in 2014 carried out by the National Institute of Health, proved that a transplant in 30 patients with sickle cell anemia worked, and reinstated the ability to reverse the effects the disease in 26 patients.

Treatment Options Available For Sickle Cell Anemia

Since the procedure involves some risks in the form of permanent infertility and mortality; many do not consider the bone marrow transplant. However, it is worth the risk if it raises some hope and put one’s life back on the track.
Read-

Stem Cell Therapy Treatment For Acute Myelofibrosis

This is how a recent case of bone marrow transplant with stem cells proved prospective for many, who are suffering from this deadly disease. The bone marrow transplant worked wonders on a Canadian resident Revée Agyepong, who was found to have sickle cell anemia ever since her toddlerhood. She received the bone marrow from her sibling Stephanie Amoah, and the transplant was successfully carried out by Dr. Andrew Daly, who runs his own stem cell health clinic in Alberta, Canada.

The successful transplant has helped Revée produce new red blood cells without any genetic mutations of sickle cell anemia.

Rather than bone marrow transplant, another successful treatment procedure is gene therapy using the CRISPR, a gene-editing technology. The gene correction technique diminishes the requirement of marrow swapping. This approach is now underway to treat sickle cell anemia. Way back in 2011, the John Hopkins Institute for Cell Engineering carried out a gene therapy procedure using the patient’s own stem cells. The procedure helped the patients with the disease to alter the genes that caused sickle cell anemia. The researchers isolated the bone marrow stem cells and converted them into iPSC cells. With reprogrammed iPSCs, embryonic stem cells were produced. Later they replaced the defective ones to produce healthier bone marrow with the help of genetic engineering techniques.

However, the trail requires a review from the FDA so that it can treat sickle cell anemia. Now, the wait is for the green signal only to put an end to the debilitating conditions of the disease.

stem cell therapy for sickle cell disease, sickle cell anemia gene replacement stem cell therapy, stem cell therapy treatment for osteoarthritis and arthritis, cell therapy for hair loss and joint disorder.

Hematopoietic Stem Cell Transplant For Aplastic Anaemia

Stem Cell Transplant

Apply Grants February 20, 2018 1

Hematopoietic Stem Cell Transplant Can Free Patients From Hazards of Aplastic Anaemia

Aplastic Anemia is a disorder of bone marrow failure. The therapeutic relief from this disorder depends on the hematopoietic stem cell transplant and Immunosuppressive therapy.

More on to AA, it is a type of blood disorder, occurring from the bone marrow failure. The hypocellular bone marrow and relentless pancytopenia characterize patients with AA. The occurrence of this disease attacks one’s immune system. And as a result, the bone marrow cannot produce marrow cells. Further, it also restricts the production of the blood platelets as well as red and white blood cells.

The prevalence of Aplastic Anemia is high amongst the pediatric children. But, it is not averse to the adults also. However, pediatrics can expect better treatment results with stem cell transplants.

Source- Flickr

Complications of AA

Frequent blood transfusion is common amongst the patients with AA. The process keeps the blood platelet counts in check. Simultaneously, immunosuppressive therapy or IST offers a better relief by curbing the autoimmune responses. And this way, it prevents causing more damage to the blood-producing cells. Patients need to take another drug therapy to avoid infections. They need to prevent contact with the outer world as well to avoid the contamination of the infection. Sometimes, these drugs do not provide any relief, thus patients are more likely to die of infections.

Treatments Options

Immunosuppressive therapy and matched bone marrow transplant offer treatment options. Well, immunosuppressive therapy or drugs are not without any relapse risks. And hence, stem cell transplantation is considered one of the best curative treatment options for the patients with AA. According to reports published online by Biology of Blood and Marrow Transplantation, patients receiving partially matched bone marrow combined with the high doses of chemotherapy are more likely to survive the disease.

Advantages of Hematopoietic Stem Cell Transplants

Transplantation reduces the further complications of Aplastic Anemia.
It reinstates the production of the blood cells and platelets.
The complications of the Graft-Versus-Host-Disease (GVHD) after the transplant are mild.
With immunosuppressive therapy, GVHD complaints can see the exit door.
It completely reduces the necessity of further medications.
Patients can enjoy their normal life as earlier, and participate in their daily activities.
Evidence Validating The Efficacy Of The Hematopoietic Stem Cell Transplant For AA
Hematopoietic Stem Cell Transplant (HSCT) is the first choice for the clinical experts when immunosuppressive therapy fails to perform.

Read-

Induced Pluripotent Stem Cells To Serve As Cancer Vaccines

And hence, stems from a sibling or matched donor are taken into account for the transplants. However, patients with half donor could also go for the transplants. A study between 2011 and 2016 showed the efficacy of the HSCT using a matched donor, half matched and unrelated matched donor.

Four types of patients received cells depending on the availability of the donors respectively. The patients received drug administration to make their body accept the bone marrow. After it, all the four patients underwent transplants with a half-matched donor, matched donors, and unrelated donor.

A few days after, they received chemotherapy. They stopped the immunosuppressive therapy too after taking it for a year.
Read-

Acute Biphenotypic Leukemia Treatment With Stem Cell Therapy

Outcomes Of The Study

Further tests on the patients suggested that there was no need for blood transfusion.

The blood cells, including the platelets, came back to normal.

No fresh requirement of medications was noticed after the discontinuation of immunosuppressive therapy.

The rate of GVHD was less than normal as well. Only a few received the after-effects of the stem cell transplants.

The further IST ensured to reduce the GVHD complaints after a few months.

Future Hopes

Source- Flickr

The shortage of matched donors can no longer be a hurdle in the way of transplants. For patients having half-matched donors or unrelated donors, HSCT is possible using chemotherapy drug cyclophosphamide. The drug is effective in destroying the diseased blood cells and producing new blood cells.

The bone marrow transplants are costly, though, they are most effective treatment options using a full or half-matched donor.

They are indeed life-saving, at the same time, they reduce the additional expenses entailing to IST, blood transfusion, and hospitalizations.

stem cell therapy for anaemia, stem cell therapy, bone marrow transplant, hematopoietic stem cell transplant, allogeneic stem cell transplantation, aplastic anaemia treatment,stem cell therapy spinal cord injury,hair transplant blogspot,hair stem cells,glioblastoma cure,stem cells hair,"stem cells",bare lymphocyte syndrome treatment,hlhs survival rate,"car-t",bare lymphocyte syndrome symptoms,bare lymphocyte syndrome,myelofibrosis treatment,glioma stem cells,stem cell heart transplant

Hematopoietic Stem Cell Therapy Transplant At The Rescue Of Acute Myelofibrosis

Stem Cell Transplant

Apply Grants February 04, 2018 1

Hematopoietic Stem Cell TherapyTransplant At The Rescue Of Acute Myelofibrosis

Stem cell therapy: Hematopoietic cell transplant (HCT) has all the powerful elements in its treatment procedures to offer better and curative treatment opportunities for patients suffering from acute Myelofibrosis. This is a rare kind of cancer, which prevents the growth of blood-producing cells, and destroys the existing and new cells more rapidly. And as a result, the bone marrow develops scars with the development of fibrous tissues within the bone marrow. So, with the occurrence of this disease, a series of health complications occur in the patients.

Health Complications of Acute Myelofibrosis

This type of leukemia belongs to the group of Myeloproliferative Neoplasms. About 30,000 of the USA citizens are suffering from this disease when their blood begins overproducing the red blood cells. So, the cells cannot produce enough blood in the body, and the body tries to move the blood production to the spleen and liver. And as the bone marrow cannot perform well, it pressurizes the spleen and liver and enlarges them. The disease causes blood clots and extreme bleeding to the people with acute myelofibrosis.
Read-

Stem Cell Therapy Treatment For Adamant Cancer Cells

Other complications include weakness, fatigue, anemia, abdominal pain, low platelet counts and prevalence of infections.

People between 50 and 70 are at high risk of developing this disease.

Stem Cell Therapy Treatment Options for Acute Myelofibrosis

The treatment options depend on the symptoms and the intensity of the complications. There are different drugs used to treat this disease.

A drug called Ruxolitinib targets the inhibitors known as JAK2 and other associated mutants. The chemical compounds of the drug effectively work and restrict the functions of the mutant protein tyrosine kinase, which can be transformed and active in people with myelofibrosis.

There are other drugs too, such as danazol, thalidomide, and erythropoietin. The most effective and the curative treatment process seem to be the stem cell therapy transplant or the bone marrow transplant. However, a fewer number of patients can benefit from the transplant, which also involves treatment-related morbidity and mortality.

Image- Flickr.com

Varied Stem Cell Therapy Options for the Treatment of Myelofibrosis

Allogeneic hematopoietic cell transplantation (HCT) is the major treatment choice for myelofibrosis. As older patients cannot stand the toxicity of the Full-Intensity Conditioning (FIC) because of its high rate of non-relapse mortality (NRM), healthy and young patients are not advised to opt for this option. This is the reason why Reduced-Intensity- Conditioning (RIC) provides much better treatment options for MF.

Read-

Acute Biphenotypic Leukemia Treatment With Stem Cell Therapy

Candidacy for RIC

Since Myelofibrosis is a disease of elderly people, and it triggers more risks associated with poor transplantation results. So, the determination to perform RIC prior to HSCT relies upon several variables such as - patients and disease-related parameters, performance capability, age, and complication biology as per the standard Dynamic International Prognostic Scoring System or (DIPSS). The determination of the candidature for the RIP is based on the risk factors. They are as follows as below:

>65 years age
Hemoglobin count <10g/dL
White blood cell counts >25x109/L
Peripheral blood blasts ≥ 1% and
Constitutional signs

Patients with low or intermediate-1 risks factors may opt for the stem cell therapy transplant as per another scoring system, Dynamic International Prognostic Scoring System, but they are not without any side effects. Certain mutations such as JAK2, MPL, and CALR cause the occurrences of primary myelofibrosis in the patients with low or intermediate-1 risk, cannot opt for the RIC. Contrary to it, patients with inhibitors or mutant proteins such as SRSF2 and ASXL1 require an instant transplant.

Eligibility of the Donor

The type of donor determines the survival rates for the patients. According to various studies, human leukocyte antigen (HLA), matched donor, preferably with siblings is the ideal donor type. It offers 75% of successful results for 2-year overall survival. It is followed by the matched unrelated donor. With this type of donor, the survival rate becomes weaker and 32% success rate is established for 2-year overall survival. And with the RIC, patients with matched donor transplant can survive for five years at a percentage of 56, matched unrelated donor survival rates is at 48%, while 34% of success rate is established for the mismatched unrelated donor type.

It is uncertain if the Splenomegaly offers any survival opportunities, prior to SCT. It leads to several health complications, including impairment of the liver functions.

stem cell therapy myelofibrosis cure, stem cell therapy bone marrow transplant, stem cell therapy for cancer, pluripotent stem cell therapy, stem cell therapy in myelofibrosis,bare lymphocyte syndrome treatment,stem cell therapy for hair loss, stem cell therapy for osteoarthritis.

Trending

Post Top Ad

May 13, 2020

Stem Cell Therapy- Sickle Cell Anemia Treatment With Stem Cell Therapy